Canada Markets closed

Lexicon Pharmaceuticals, Inc. (LXRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.1300-0.0200 (-0.63%)
At close: 04:00PM EST
3.1300 0.00 (0.00%)
After hours: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close3.1500
Open3.0700
Bid3.0300 x 1200
Ask3.6000 x 1100
Day's Range2.9150 - 3.1600
52 Week Range2.9150 - 9.6500
Volume821,398
Avg. Volume656,741
Market Cap466.045M
Beta (5Y Monthly)1.43
PE Ratio (TTM)N/A
EPS (TTM)-0.4870
Earnings DateMar. 08, 2022 - Mar. 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
  • GlobeNewswire

    Lexicon Pharmaceuticals Outlines Major Potential Value Drivers for 2022 at 40th Annual J.P. Morgan Healthcare Conference

    NDA submitted for sotagliflozin in heart failure with an expected launch in 2H 2022, if approved LX9211 neuropathic pain Phase 2 studies expected to read out in 1H 2022 THE WOODLANDS, Texas, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is outlining major potential value drivers for 2022 at this morning’s presentation at the 40th Annual J.P. Morgan Healthcare Conference. Lexicon submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA)

  • GlobeNewswire

    Lexicon Pharmaceuticals to Participate in The 40th Annual J.P. Morgan Healthcare Conference

    THE WOODLANDS, Texas, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. ET. A webcast of the event will be available in the “Events” section of the Lexicon website at www.lexpharma.com. An archived version of the webcast will be available on the website for two weeks. About Lexicon Pharmace

  • Zacks

    Lexicon (LXRX) Submits NDA to the FDA for Cardiovascular Drug

    Lexicon (LXRX) submits an application to the FDA seeking approval for sotagliflozin to lower the risk of cardiovascular death and hospitalization and urgent visits for heart failure in adult patients.